# Determining Minimal Residual Disease Using ctDNA Deep Sequencing

> **NCT07660627** · NA · RECRUITING · sponsor: **Masaryk Memorial Cancer Institute** · enrollment: 34 (estimated)

## Conditions studied

- Esophageal Adenocarcinoma
- Gastric Cancer
- Pancreatic Cancer

## Interventions

- **DIAGNOSTIC_TEST:** NGS sequencing of mutations selected based on sequencing of primary tumors

## Key facts

- **NCT ID:** NCT07660627
- **Lead sponsor:** Masaryk Memorial Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-22
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2026-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07660627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07660627, "Determining Minimal Residual Disease Using ctDNA Deep Sequencing". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07660627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*